Partner With Us
Fueling the translation of our mRNA platform
Chief Executive Officer
Chief Medical Officer
Chief Scientific Officer
Chief Financial Officer
Chief Business Officer
Chief Human Resources Officer
Chief Legal Officer
Senior Vice President, Research and Process Development
Dan joined our board of directors in 2012 with more than 25 years of experience serving in management positions in the biotechnology and pharmaceutical industries. Dan spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CEO, Dan led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX® (Cetuximab), a novel cancer treatment. As CFO, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, Dan served in various financial positions at Bristol-Myers Squibb over a 15-year tenure.
Dan has advised and served as executive chair or member of the board of directors for a number of private biopharmaceutical companies, including Stromedix, Inc. (until its acquisition by Biogen Idec in February 2012); Avila Therapeutics, Inc. (until its acquisition by Celgene Corporation in February 2012); Nimbus Discovery, LLC; Edimer Pharmaceuticals; Ember Therapeutics, Inc. and BIND Therapeutics Inc. He currently serves on the board of directors of Blueprint Medicines, Bluebird Bio, Proclara Biosciences, Surface Oncology and Eleven Biotherapeutics, Inc. Dan received his BA in mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.
Jean-François is a partner and cofounder and focuses on new advances in biology and drug-discovery technologies as well as novel therapeutics. He joined our board of directors in 2011. Jean-Francois is also chair of the board of IFM Therapeutics and serves on the boards of F-star, Intellia Therapeutics (NASDAQ: NTLA), Kyn Therapeutics, Spero Therapeutics.
Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Arteaus Therapeutics (acquired by Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM, acquired by Fresenius Medical) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Lilly). He was also an investor in Achillion (NASDAQ: ACHN), Annovation Biopharma (acquired by The Medicines Company), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) as well as a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).
Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.
Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art. He received his MD from Paris University School of Medicine, and his MBA from Columbia University.
Brian joined our board of directors in 2011 and is a partner at Abingworth in the company's Boston office. He currently works with Abingworth's London and Menlo Park offices to source and support deals across a wide range of therapeutic areas and stages of development from start-ups to late-stage venture capital investments.
Brian has more than 20 years of investing, business development, operational and R&D experience in both biotechnology and large pharma companies. Prior to joining Abingworth, Brian was a partner at SR One and established the company's Boston office in 2010. He previously led the firm’s investments in Dicerna Pharmaceuticals and SpringLeaf Therapeutics. He joined SR One from Sirtris Pharmaceuticals, where he was responsible for corporate development, operations and post-merger integration following the $720 million acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Brian was with Alantos Pharmaceuticals, where he played key roles in the R&D and business development activities and led many aspects of the post-merger integration following the $300 million acquisition of Alantos by Amgen in 2007. He began his career in R&D at the Japanese pharma Eisai, where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas.
Brian is an inventor on over 25 patents and patent applications and is the senior author of a number of scientific publications. He currently serves on the Industry Advisory Boards for NYU Medical School and the National Brain Tumor Society, as a mentor for MassBio’s MassCONNECT, and as a peer reviewer/editorial board member for numerous journals and research funding authorities. Brian received his MS and PhD degrees in organic chemistry from the University of Michigan and his BS in chemistry from the University of Massachusetts, where he was a Shapiro scholar.
Owen Hughes currently serves as the chief executive officer at Cullinan Oncology focused on oncological drug development. Prior to Cullinan, Mr. Hughes was the chief business officer and head of corporate development at Intarcia Therapeutics. Mr Hughes also served as director at Bain Capital Public Equity, a multibillion-dollar hedge fund. There, he comanaged public and private healthcare investments, including those in the biopharmaceutical, medtech and services segments. Mr. Hughes has over 16 years of Wall Street experience on both the buy and sell sides and serves on the board of both Radius Health (Nasdaq: RDUS) and Malin PLC (ESM: MLC).